Updated 36d ago
Heron Therapeutics is a commercial-stage company whose lead product ZYNRELEF treats postoperative pain and is already approved; the company also markets CINVANTI for chemotherapy-induced nausea and vomiting, but a patent ruling in June 2026 eliminated its protection from generic competition, forcing the company to pursue strategic alternatives while relying on ZYNRELEF's growth to sustain operations.
Heron built a three-product acute/oncology franchise, and a June 2026 Delaware court ruling invalidating CINVANTI patents eliminated the revenue floor that made the model work. ZYNRELEF grew 35% year-over-year in Q2 2026 and APONVIE 74%, but together they generated only $15M quarterly against a cash position of $43M with no stated runway. The strategic alternatives process, a restructured credit facility, and withdrawn guidance signal a company racing against generic CINVANTI erosion before its acute care franchise reaches self-sufficiency.
Current Thesis Drivers
What could change the thesis?
Generated from public SEC filings and disclosures. For informational purposes only — not investment advice. Always conduct your own research before making investment decisions.
Thesis log
Tracked in real time as it happened — not reconstructed after the fact
Key value driver
The most decisive event ahead
Bull and bear case
Both sides of the thesis, argued
Pipeline
1 programs · 1 catalysts